REVELATION BIOSCIENCES, INC.

Revelation Biosciences (REVB) shows no detected cyber incidents or red-flag 8-K filings in the last 90 days, suggesting near-term operational stability. However, a quiet recent period doesn't eliminate structural risks—particularly dilution exposure and financing runway, which are critical for early-stage biotech. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk score, maps financing history and cash burn, and flags AI-driven regulatory signals often missed in routine screening. The full $49 Report adds dilution quantification, 12-month event history, financing trajectory analysis, and AI risk flagging across SEC filings.